JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias

Ono, Katsushige; Iwasaki, Yu‐ki; Akao, Masaharu; Ikeda, Takanori; Ishii, Kuniaki; Inden, Yasuya; Kusano, Kengo; Kobayashi, Yoshinori; Koretsune, Yukihiro; Sasano, Tetsuo; Sumitomo, Naokata; Takahashi, Naohiko; Niwano, Shinichi; Hagiwara, Nobuhisa; Hisatome, Ichiro; Furukawa, Tetsushi; Honjo, Haruo; Maruyama, Toru; Murakawa, Yuji; Yasaka, Masahiro; Watanabe, Eiichi; Aiba, Takeshi; Amino, Mari; Itoh, Hideki; Ogawa, Hisashi; Okumura, Yasuo; Aoki‐Kamiya, Chizuko; Kishihara, Jun; Kodani, Eitaro; Kubo, Takashi; Sakamoto, Yusuke; Sato, Kazuhiro; Shiga, Tsuyoshi; Shinohara, Tetsuji; Suzuki, Atsushi; Suzuki, Shinya; Sekiguchi, Yukio; Nagase, Satoshi; Hayami, Noriyuki; Harada, Masahide; Fujino, Tadashi; Makiyama, Takeru; Maruyama, Mitsunori; Miake, Junichiro; Muraji, Shota; Murata, Hiroshige; Morita, Norishige; Yokoshiki, Hisashi; Yoshioka, Koichiro; Yodogawa, Kenji; Inoue, Hiroshi; Okumura, Ken; Kimura, Takeshi; Tsutsui, Hiroyuki; Shimizu, Wataru

doi:10.1253/circj.cj-20-1212

Cited by 71 publications

(72 citation statements)

References 956 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The indication of left atrial appendage closure accorded with the Japanese Circulation Society guidelines [ 13 ]. Candidates were those with NVAF who had high risks of experiencing systemic embolisms, and were highly recommended to receive anti-coagulation therapy, according to the CHADS 2 score and CHA 2 DS 2 -VASc score [ 14 ]. Furthermore, the candidates had to satisfy either of the following: (1) those with HAS-BLED score ≥3 points, (2) those with multiple histories of trauma due to falling, (3) those with cerebral amyloid angiopathy, (4) those who had required multiple anti-platelets for over one year, and (5) those with histories of major bleeding assigned to BARC type 3–5.…”

Section: Methodsmentioning

confidence: 99%

Comparison in Short-Term Safety and Efficacy between New-Generation WATCHMAN FLX and Conventional WATCHMAN 2.5 for Percutaneous Left Atrial Appendage Closure

Fukuda

Imamura

Tanaka

et al. 2022

JCM

View full text Add to dashboard Cite

Background: Percutaneous left atrial appendage closure using the WATCHMAN system, to prevent thrombosis and minimize anti-coagulant use in patients with non-valvular atrial fibrillation, has recently been introduced. The safety and efficacy of new-generation WATCHMAN FLX, as compared to conventional WATCHMAN 2.5, remain unknown. Methods: Consecutive patients who received percutaneous left atrial appendage closure using the WATCHMAN system in our institute, between June 2020 and December 2021, were retrospectively analyzed. Safety and efficacy during the 45-day observational period were compared between the two devices. Results: A total of 93 patients (73.0 ± 7.3 years old, 63 men) who received WATCHMAN FLX (n = 44) or WATCHMAN 2.5 (n = 49) were included. The device implant success rate was 100% in the FLX device group and 98% in the 2.5 device group. There were no procedure-related complications in the FLX group, and one non-relevant pericardial effusion in the 2.5 device group. During the 45-day observational period, there were no procedure-related adverse events. No patients in the FLX group had a peri-device leak >3 mm, whereas two patients in the 2.5 device group had a peri-device leak >3 mm. Anti-coagulants could be terminated in most of the patients (85% versus 88%; p = 0.68). Conclusions: Percutaneous left atrial appendage closure using new-generation WATCHMAN FLX seemed to be as safe and effective as conventional WATCHMAN 2.5 during the short-term observational period.

show abstract

Section: Methodsmentioning

confidence: 99%

Comparison in Short-Term Safety and Efficacy between New-Generation WATCHMAN FLX and Conventional WATCHMAN 2.5 for Percutaneous Left Atrial Appendage Closure

Fukuda

Imamura

Tanaka

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…The warfarin-treated group was categorized into three groups according to their status and depending on the prothrombin time-international normalized ratio (PT- INR) control: within, below, or above the therapeutic range. The therapeutic range refers to PT-INR values ranging from 2.0 to 3.0 (1.6–2.6 in patients over 70 years), as defined in the 2020 Japanese Circulation Society Guideline on Pharmacotherapy of Cardiac Arrhythmias 13 . All four types of DOACs have specific dose reduction criteria based on the patient’s renal function, age, and body weight, and as summarized in the guidelines mentioned above, which describe five subgroups: appropriate standard-dose, appropriate low-dose, overdose, underdose, and contraindication.…”

Section: Methodsmentioning

confidence: 99%

Impact of anticoagulants on the clinical outcomes of colonic diverticular bleeding comparing warfarin and direct oral anticoagulants

Chang

Nishida

Hosokawa

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Recently, direct oral anticoagulants (DOACs) have been widely used as antithrombotic agents to replace warfarin, but their clinical impact in patients with gastrointestinal bleeding is unclear. We compared the effects of warfarin and DOACs on the outcomes of patients with colonic diverticular bleeding. The patients were divided into warfarin and DOAC groups. We compared the clinical outcomes and the effect of the DOAC dosing and examined any readmissions due to colonic diverticular bleeding within 1 year. A total of 95 events (warfarin group: n = 43 and DOAC group: n = 52) were included. Compared with the warfarin group, the DOAC group was significantly older, had a lower rate of concomitant antiplatelet agents, and a shorter hospital stay, but no significant differences were found in the other clinical outcomes. Thirty-seven patients (71.2%) in the DOAC group had appropriate dosing, whereas 15 patients (28.9%) had an inappropriate dose. The patients with overdose or contraindications had significantly lower minimum hemoglobin levels. In the univariate analysis, prior hospitalization for colonic diverticular bleeding was a significant predictor of readmission. Compared with warfarin, patients with colonic diverticular bleeding treated with DOACs were older and had shorter hospital stays, and the inappropriate use of DOACs may worsen outcomes.

show abstract

“…( 9) Mid-esophageal 2-chamber view (90°, vertical plane). (10) Mid-esophageal LAA view (90°, rotated counterclockwise from the 2-chamber view). (11) Mid-esophageal LAA basal view (120°).…”

Section: ▋ 123 Anatomy and Standard Views In Teementioning

confidence: 99%

“…Cardioversion strategy with the use of TEE is recognized as one of the acceptable strategies for cardioversion. [8][9][10] On the other hand, TEE is often omitted in patients with no allergy to contrast media who are undergoing catheter ablation when the existence of thrombi in the LAA is excluded by preoperative contrast-enhanced cardiac computed tomography (CT) (see Clinical Question). TEE should also be considered when searching for a cardiac embolic source in patients with cerebral embolism of unknown origin.…”

Section: ▋ 13 Indications and Contraindications For Teementioning

confidence: 99%